Prasannan Latha, Flynn Joseph T, Levine John E
Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI 48106, USA.
Pediatr Nephrol. 2003 Mar;18(3):283-5. doi: 10.1007/s00467-002-1051-7. Epub 2003 Feb 7.
A 17-year-old patient with sickle cell-beta thalassemia undergoing treatment with home iron chelation therapy inadvertently received ten times the recommended dose of intravenous deferoxamine. Acute renal failure (ARF) developed within hours. Immediate treatment with high-efficiency hemodialysis resulted in the prompt return of renal function after only one hemodialysis session. No long-term nephrotoxic effects of the deferoxamine overdose developed after more than 1 year of follow-up. Children with sickle cell disease who are on intravenous deferoxamine and their parents should be cautioned about the possibility of ARF with overdose due to malfunction of the pump and/or inadequate monitoring during treatment. ARF, should it occur in such children, appears to respond well to treatment with high-efficiency hemodialysis.